Asprius Lifesciences, a pharmaceutical company based in Gujarat, has made a significant announcement
regarding the development of a treatment for Diabetic Neuropathy, a condition that leads to nerve damage
in peripheral areas of the body. The company has already applied for a patent for its Fixed-Dose Combination
(FDC) drug, which shows great promise in addressing peripheral neuropathy, a prevalent condition affecting
more than 2 percent of the global population.